Literature DB >> 24578247

Stability of [-2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions.

Tsukasa Igawa1, Kosuke Takehara, Toru Onita, Kazuto Ito, Hideki Sakai.   

Abstract

BACKGROUND: The clinical usefulness of [-2]pro-PSA (where PSA is prostate-specific antigen) in prostate cancer diagnosis has been emphasized in recent studies. To determine proper blood sample handling conditions for [-2]pro-PSA evaluation, we analyzed the preanalytical stability of [-2]pro-PSA.
METHODS: Blood samples from 22 Japanese males were stored under various conditions before total PSA (tPSA), free PSA, and [-2]pro-PSA concentrations were measured, and the preanalytical stability of [-2]pro-PSA and the changes in the Prostate Health Index (phi) were assessed.
RESULTS: [-2]Pro-PSA was stable in serum for at least 24 hr at both room temperature (RT) and at 4°C. However, [-2]pro-PSA levels in whole blood increased rapidly over time, particularly at RT. Mean recovery (%) of [-2]pro-PSA in whole blood at RT was >110% at 1 hr after drawing of blood. The phi tended to increase over time in a pattern similar to the change in[-2]pro-PSA.
CONCLUSIONS: Preanalytical stability was lower for [-2]pro-PSA than for free PSA or tPSA. Whole-blood [-2]pro-PSA increased in a time-dependent manner, particularly at RT. Thus, whole blood samples collected at RT should be centrifuged within 1 hr after drawing. The [-2]pro-PSA in serum is stable for at least 24 hr at both RT and at 4°C.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Prostate Health Index; [−2]pro-PSA; free PSA; preanalytical stability; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24578247      PMCID: PMC6807334          DOI: 10.1002/jcla.21687

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  22 in total

1.  A comprehensive nomenclature for serine proteases with homology to tissue kallikreins.

Authors:  Ake Lundwall; Vimla Band; Michael Blaber; Judith A Clements; Yves Courty; Eleftherios P Diamandis; Hans Fritz; Hans Lilja; Johan Malm; Lois J Maltais; A Yvonne Olsson; Constantina Petraki; Andreas Scorilas; Georgia Sotiropoulou; Ulf-Håkan Stenman; Carsten Stephan; Maroulio Talieri; George M Yousef
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

2.  Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.

Authors:  A Kumar; S D Mikolajczyk; A S Goel; L S Millar; M S Saedi
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

3.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

Authors:  A W Partin; W J Catalona; P C Southwick; E N Subong; G H Gasior; D W Chan
Journal:  Urology       Date:  1996-12       Impact factor: 2.649

4.  Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.

Authors:  Lori J Sokoll; Daniel W Chan; Stephen D Mikolajczyk; Harry G Rittenhouse; Cindy L Evans; Harry J Linton; Leslie A Mangold; Phaedre Mohr; Georg Bartsch; Helmut Klocker; Wolfgang Horninger; Alan W Partin
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

5.  Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.

Authors:  Kazuto Ito; Mai Miyakubo; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

6.  Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.

Authors:  Masood A Khan; Alan W Partin; Harry G Rittenhouse; Stephen D Mikolajczyk; Lori J Sokoll; Daniel W Chan; Robert W Veltri
Journal:  J Urol       Date:  2003-09       Impact factor: 7.450

7.  A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.

Authors:  Hyesook Yoon; Sachiko I Blaber; Mekdes Debela; Peter Goettig; Isobel A Scarisbrick; Michael Blaber
Journal:  Biol Chem       Date:  2009-04       Impact factor: 3.915

8.  Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.

Authors:  Iacovos P Michael; Georgios Pampalakis; Stephen D Mikolajczyk; Johan Malm; Georgia Sotiropoulou; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2006-03-03       Impact factor: 5.157

9.  Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.

Authors:  Fred C G J Sweep; Herbert A Fritsche; Massimo Gion; George G Klee; Manfred Schmitt
Journal:  Int J Oncol       Date:  2003-12       Impact factor: 5.650

Review 10.  From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.

Authors:  Satoshi Hori; Jean-Sebastien Blanchet; John McLoughlin
Journal:  BJU Int       Date:  2012-07-03       Impact factor: 5.588

View more
  4 in total

Review 1.  Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.

Authors:  Kazuto Ito; Yuji Fujizuka; Kiyohide Ishikura; Bernard Cook
Journal:  Int J Clin Oncol       Date:  2014-08-20       Impact factor: 3.402

2.  Detection of ISUP ≥2 prostate cancers using multiparametric MRI: prospective multicentre assessment of the non-inferiority of an artificial intelligence system as compared to the PI-RADS V.2.1 score (CHANGE study).

Authors:  Olivier Rouvière; Rémi Souchon; Carole Lartizien; Adeline Mansuy; Laurent Magaud; Matthieu Colom; Marine Dubreuil-Chambardel; Sabine Debeer; Tristan Jaouen; Audrey Duran; Pascal Rippert; Benjamin Riche; Caterina Monini; Virginie Vlaeminck-Guillem; Julie Haesebaert; Muriel Rabilloud; Sébastien Crouzet
Journal:  BMJ Open       Date:  2022-02-09       Impact factor: 2.692

3.  A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data.

Authors:  Shea P O'Connell; Maria Frantzi; Agnieszka Latosinska; Martyn Webb; William Mullen; Martin Pejchinovski; Mark Salji; Harald Mischak; Colin S Cooper; Jeremy Clark; Daniel S Brewer
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 4.  Biomarkers for prostate cancer detection and risk stratification.

Authors:  Mark W Farha; Simpa S Salami
Journal:  Ther Adv Urol       Date:  2022-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.